Overview

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Glipizide
Hypoglycemic Agents
Maleic acid
Rosiglitazone